Liraglutide Attenuates Hepatic Ischemia-Reperfusion Injury by Modulating Macrophage Polarization. 2022

Shang-Lin Li, and Zhi-Min Wang, and Cong Xu, and Fu-Heng Che, and Xiao-Fan Hu, and Rui Cao, and Ya-Nan Xie, and Yang Qiu, and Hui-Bo Shi, and Bin Liu, and Chen Dai, and Jun Yang
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Ischemia-reperfusion injury (IRI) is a common complication associated with liver surgery, and macrophages play an important role in hepatic IRI. Liraglutide, a glucagon-like peptide-1 (GLP-1) analog primarily used to treat type 2 diabetes and obesity, regulates intracellular calcium homeostasis and protects the cardiomyocytes from injury; however, its role in hepatic IRI is not yet fully understood. This study aimed to investigate whether liraglutide can protect the liver from IRI and determine the possible underlying mechanisms. Our results showed that liraglutide pretreatment significantly alleviated the liver damage caused by ischemia-reperfusion (I/R), as evidenced by H&E staining, serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, and TUNEL staining. Furthermore, the levels of inflammatory cytokines elicited by I/R were distinctly suppressed by liraglutide pretreatment, accompanied by significant reduction in TNF-α, IL-1β, and IL-6 levels. Furthermore, pretreatment with liraglutide markedly inhibited macrophage type I (M1) polarization during hepatic IRI, as revealed by the significant reduction in CD68+ levels in Kupffer cells (KCs) detected via flow cytometry. However, the protective effects of liraglutide on hepatic IRI were partly diminished in GLP-1 receptor-knockout (GLP-1R-/-) mice. Furthermore, in an in vitro study, we assessed the role of liraglutide in macrophage polarization by examining the expression profiles of M1 in bone marrow-derived macrophages (BMDMs) from GLP-1R-/- and C57BL/6J mice. Consistent with the results of the in vivo study, liraglutide treatment attenuated the LPS-induced M1 polarization and reduced the expression of M1 markers. However, the inhibitory effect of liraglutide on LPS-induced M1 polarization was largely abolished in BMDMs from GLP-1R-/- mice. Collectively, our study indicates that liraglutide can ameliorate hepatic IRI by inhibiting macrophage polarization towards an inflammatory phenotype via GLP-1R. Its protective effect against liver IRI suggests that liraglutide may serve as a potential drug for the clinical treatment of liver IRI.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D000069450 Liraglutide An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN. NN 2211,NN-2211,NN2211,Saxenda,Victoza
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015427 Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA. Ischemia-Reperfusion Injury,Injury, Ischemia-Reperfusion,Injury, Reperfusion,Reperfusion Damage,Damage, Reperfusion,Injury, Ischemia Reperfusion,Ischemia Reperfusion Injury,Ischemia-Reperfusion Injuries,Reperfusion Damages,Reperfusion Injuries
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Shang-Lin Li, and Zhi-Min Wang, and Cong Xu, and Fu-Heng Che, and Xiao-Fan Hu, and Rui Cao, and Ya-Nan Xie, and Yang Qiu, and Hui-Bo Shi, and Bin Liu, and Chen Dai, and Jun Yang
February 2024, Hepatobiliary & pancreatic diseases international : HBPD INT,
Shang-Lin Li, and Zhi-Min Wang, and Cong Xu, and Fu-Heng Che, and Xiao-Fan Hu, and Rui Cao, and Ya-Nan Xie, and Yang Qiu, and Hui-Bo Shi, and Bin Liu, and Chen Dai, and Jun Yang
January 2021, Frontiers in pharmacology,
Shang-Lin Li, and Zhi-Min Wang, and Cong Xu, and Fu-Heng Che, and Xiao-Fan Hu, and Rui Cao, and Ya-Nan Xie, and Yang Qiu, and Hui-Bo Shi, and Bin Liu, and Chen Dai, and Jun Yang
January 2021, Oxidative medicine and cellular longevity,
Shang-Lin Li, and Zhi-Min Wang, and Cong Xu, and Fu-Heng Che, and Xiao-Fan Hu, and Rui Cao, and Ya-Nan Xie, and Yang Qiu, and Hui-Bo Shi, and Bin Liu, and Chen Dai, and Jun Yang
January 2021, International journal of medical sciences,
Shang-Lin Li, and Zhi-Min Wang, and Cong Xu, and Fu-Heng Che, and Xiao-Fan Hu, and Rui Cao, and Ya-Nan Xie, and Yang Qiu, and Hui-Bo Shi, and Bin Liu, and Chen Dai, and Jun Yang
December 2000, American journal of physiology. Cell physiology,
Shang-Lin Li, and Zhi-Min Wang, and Cong Xu, and Fu-Heng Che, and Xiao-Fan Hu, and Rui Cao, and Ya-Nan Xie, and Yang Qiu, and Hui-Bo Shi, and Bin Liu, and Chen Dai, and Jun Yang
March 2017, Naunyn-Schmiedeberg's archives of pharmacology,
Shang-Lin Li, and Zhi-Min Wang, and Cong Xu, and Fu-Heng Che, and Xiao-Fan Hu, and Rui Cao, and Ya-Nan Xie, and Yang Qiu, and Hui-Bo Shi, and Bin Liu, and Chen Dai, and Jun Yang
February 2021, Aging,
Shang-Lin Li, and Zhi-Min Wang, and Cong Xu, and Fu-Heng Che, and Xiao-Fan Hu, and Rui Cao, and Ya-Nan Xie, and Yang Qiu, and Hui-Bo Shi, and Bin Liu, and Chen Dai, and Jun Yang
January 2023, The Journal of surgical research,
Shang-Lin Li, and Zhi-Min Wang, and Cong Xu, and Fu-Heng Che, and Xiao-Fan Hu, and Rui Cao, and Ya-Nan Xie, and Yang Qiu, and Hui-Bo Shi, and Bin Liu, and Chen Dai, and Jun Yang
December 2022, Inflammation,
Shang-Lin Li, and Zhi-Min Wang, and Cong Xu, and Fu-Heng Che, and Xiao-Fan Hu, and Rui Cao, and Ya-Nan Xie, and Yang Qiu, and Hui-Bo Shi, and Bin Liu, and Chen Dai, and Jun Yang
November 2018, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology,
Copied contents to your clipboard!